Mazdutide vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
MazdutideAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- ~7 days
- ~2–5 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 5–10 mg
- Frequency
- Once weekly
- Daily to several times per week
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —